{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:09:16Z","timestamp":1779192556129,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Fluticasone propionate (Fp) is an inhaled corticosteroid with well-established safety and efficacy profiles. This study evaluated the systemic pharmacokinetics of Fp inhaled from a novel, inhalation-driven multidose dry powder inhaler (MDPI) that does not require coordination of actuation with inhalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This was a single-center, open-label, randomized, 3-period crossover, single-dose study in healthy Japanese and Caucasian subjects aged 20\u201345 years, inclusive. Subjects were randomized to one of six treatment sequences including combinations of four inhalations of Fp MDPI 100\u2009\u03bcg (400\u2009\u03bcg total dose), Fp MDPI 200\u2009\u03bcg (800\u2009\u03bcg total dose), and Fp Diskus\n                      <jats:sup>\u00ae<\/jats:sup>\n                      100\u2009\u03bcg (400\u2009\u03bcg total dose). The primary objective was to assess pharmacokinetics (maximum plasma concentration [C\n                      <jats:sub>max<\/jats:sub>\n                      ] and area under concentration-vs.-time curve [AUC]) for each treatment. Safety and tolerability were also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty subjects (15 Caucasian, 15 Japanese) met entry criteria and were randomized; all 30 subjects completed the study. At the inhaled Fp total doses evaluated (400 and 800\u2009\u03bcg), the shapes of plasma concentration-vs.-time curves and systemic exposure (AUC\n                      <jats:sub>0-t<\/jats:sub>\n                      and C\n                      <jats:sub>max<\/jats:sub>\n                      ) were similar in Japanese and Caucasian subjects. Geometric mean ratios (Japanese\/Caucasian) for AUC\n                      <jats:sub>0-t<\/jats:sub>\n                      ranged from 1.11 to 1.15, and for C\n                      <jats:sub>max<\/jats:sub>\n                      ranged from 0.90 to 1.05, with no substantial differences between ethnic groups. In both ethnic groups, and in the combined population, systemic exposure (AUC\n                      <jats:sub>0-t<\/jats:sub>\n                      and C\n                      <jats:sub>max<\/jats:sub>\n                      ) was highest for Fp MDPI 800\u2009\u03bcg, followed by Fp MDPI 400\u2009\u03bcg, and last by Fp Diskus 400\u2009\u03bcg. No clinical laboratory, vital signs, or physical examination findings were considered clinically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Systemic exposure following inhaled single doses of Fp was comparable in healthy adult Japanese and Caucasian subjects for each total dose and inhaler. The new MDPI provided more efficient drug delivery than Diskus, suggesting that Fp MDPI may provide similar clinical efficacy at a lower inhaled dose compared with Diskus. Single-dose inhaled Fp (400\u2013800\u2009\u03bcg) was generally well tolerated in healthy adults.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jamp.2015.1226","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T15:02:04Z","timestamp":1448982124000},"page":"207-214","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus\n                    <sup>\u00ae<\/sup>\n                    in Healthy Adults"],"prefix":"10.1177","volume":"29","author":[{"given":"Apinya Bee","family":"Vutikullird","sequence":"first","affiliation":[{"name":"WCCT Global"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Song","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Steinfeld","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"key":"e_1_3_3_2_2","volume-title":"Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma","year":"2007","unstructured":"Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma: National Heart, Lung, and Blood Institute, US Department of Health and Human Services, Bethesda, MD; 2007."},{"key":"e_1_3_3_3_2","unstructured":"Global Strategy for Asthma Management and Prevention Global Initiative for Asthma (GINA). 2015. Available at: http:\/\/www.ginasthma.org. Accessed November17 2015."},{"key":"e_1_3_3_4_2","first-page":"CD003135","article-title":"Inhaled fluticasone versus placebo for chronic asthma in adults and children","author":"Adams NP","year":"2005","unstructured":"Adams NP, , Bestall JC, , Lasserson TJ, , and Jones PW: Inhaled fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev. 2005; CD003135.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_5_2","unstructured":"Flovent HFA [package insert]: GlaxoSmithKline Research Triangle Park NC; 2014."},{"key":"e_1_3_3_6_2","unstructured":"Flovent Diskus [package insert]: GlaxoSmithKline Research Triangle Park NC; 2014."},{"key":"e_1_3_3_7_2","first-page":"A45","article-title":"Efficacy of albuterol multidose dry powder inhaler versus placebo in subjects 12 years of age and older with persistent asthma [abstract P74]","volume":"113","author":"Raphael G","year":"2014","unstructured":"Raphael G, , Taveras H, , Iverson H, , O'Brien C, , and Miller D: Efficacy of albuterol multidose dry powder inhaler versus placebo in subjects 12 years of age and older with persistent asthma [abstract P74]. Ann Allergy Asthma Immunol. 2014; 113:A45\u2013A46.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_3_3_8_2","article-title":"12- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma","author":"Raphael G","year":"2015","unstructured":"Raphael G, , Taveras H, , Iverson H, , O'Brien C, , and Miller D: 12- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma. J Asthma, 2015.","journal-title":"J Asthma"},{"key":"e_1_3_3_9_2","first-page":"S40","article-title":"A novel albuterol multidose dry powder inhaler in adult and adolescent patients with exercise-induced bronchoconstriction: a single-dose study [abstract P56]","volume":"113","author":"Ostrom N","year":"2014","unstructured":"Ostrom N, , Taveras H, , Iverson H, , and Pearlman D: A novel albuterol multidose dry powder inhaler in adult and adolescent patients with exercise-induced bronchoconstriction: a single-dose study [abstract P56]. Ann Allergy Asthma Immunol. 2014; 113:S40.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14095-11"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12263"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01493.x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.02.007"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2014.07.001"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2013.1040"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2011.0884"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039001-00002"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10238"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1211\/0022357991776967"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039001-00006"}],"container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jamp.2015.1226","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2015.1226","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2015.1226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:46:37Z","timestamp":1779191197000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jamp.2015.1226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,1]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4,1]]}},"alternative-id":["10.1089\/jamp.2015.1226"],"URL":"https:\/\/doi.org\/10.1089\/jamp.2015.1226","relation":{},"ISSN":["1941-2711","1941-2703"],"issn-type":[{"value":"1941-2711","type":"print"},{"value":"1941-2703","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,1]]}}}